Articles from Optinose, Inc.

Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time

Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose’s common stock will trade on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis under a new CUSIP number 68404V209 and Optinose’s existing trading symbol “OPTN.”

YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 1:30 p.m. ET.

Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023

Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time

YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option awards to purchase an aggregate of 185,000 shares of its common stock to eight new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer.

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society.

YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET.

Company reports Q2 2024 XHANCE net revenue of $20.5 million, an increase of 5% compared to Q2 2023

Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time

YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE® (fluticasone propionate) has been added to Express Scripts’ national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in the U.S. with more than 24 million lives.

YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.

Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023

Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time

Led by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors

Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time

YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps

PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis

Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time

XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and ReOpen2)

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 3:30 p.m. ET.

Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance

Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern Time

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET.

Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance

Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time

YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option award to purchase 100,000 shares of its common stock to a new employee as an inducement material for accepting employment with OptiNose. The stock option award was granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Jefferies Healthcare Conference on June 9, 2023 at 10:00 a.m. ET.

Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis

Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time

YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET.

Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million

Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time

YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to request approval of XHANCE as a treatment for chronic rhinosinusitis. XHANCE® (fluticasone propionate) nasal spray is a drug device combination product combining an anti-inflammatory drug with the innovative Exhalation Delivery System™ (EDS™) that is designed to uniquely deliver drug high and deep into nasal passages. The sNDA submission is based on data from the two Phase 3 clinical trials from the ReOpen Program in patients suffering from chronic sinusitis and was submitted to the FDA on February 16, 2023.

Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors

YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer.

YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Michele Janis, Acting Chief Financial Officer, will leave Optinose to accept a CFO opportunity at a privately-held company. Ms. Janis will continue to serve as Acting Chief Financial Officer until her departure on December 30, 2022.

$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and warrants to purchase 26,320,000 shares of its common stock at a combined public offering price of $1.90 per share and accompanying warrant, for gross proceeds of approximately $50 million to Optinose, before deducting underwriting discounts and commissions and offering expenses payable by Optinose. All shares of common stock and accompanying warrants in the offering are being offered by Optinose. The offering is expected to close on or about November 23, 2022, subject to the satisfaction of customary closing conditions.

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. All shares of common stock and accompanying warrants to be sold in the offering will be sold by Optinose. In addition, Optinose is expected to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the total number of shares of common stock and/or warrants to purchase shares of common stock to be offered at the public offering price, less the underwriting discount. The public offering price has not yet been determined. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023

YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQOPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen2 phase 3 clinical trial will be presented at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting in Louisville, Kentucky on November 12, 2022.

Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time

Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program